Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.
Latest from Jung Won Shin
Plus deals involving Insilico/Qilu, Insilico/Hygtia, AstraZeneca/AbelZeta, Alteogen/Tesaro, Ellipses/Innolake and more.
AriBio reaches an exclusive global out-licensing deal with Restari for its next generation PDE-5 inhibitor.
A CEPI-supported partnership between MSD Hilleman and SK bioscience aims to improve Ebola vaccine manufacturing and supply.
Amid Pfizer’s acquisition of Metsera and Hanmi’s novel contender moving to the approval stage, South Korean obesity assets are poised to attract more interest from global pharma firms and investors.
Novo Nordisk talks about opportunity for obesity deals, Bayer looks for precision medicines and Boehringer Ingelheim tries to make big pharma small, plus more from day four of J.P. Morgan.
Sanofi's Paul Hudson on vaccine M&A, BMS's Lenkowsky on its MFN deal, Gilead's business development priorities, BI prepares for obesity/MASH readouts, GSK talks AI and AstraZeneca buys Modella AI, plus more from day three of J.P. Morgan.